Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA; Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, Johns Hopkins University, Baltimore, MD, USA.
Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, Johns Hopkins University, Baltimore, MD, USA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
HPB (Oxford). 2024 Oct;26(10):1280-1290. doi: 10.1016/j.hpb.2024.07.403. Epub 2024 Jul 8.
Minimally invasive pancreatic surgery (MIPS), when selectively utilized, has been shown to hasten recovery with outcomes comparable to open approaches, but access may not be equitable. This study explored variation in utilization of MIPS for pancreatic cancer.
The National Cancer Database was queried to identify patients diagnosed with a primary pancreatic neoplasm from 2010 to 2020. Study participants had diagnoses of clinical or pathologic stage 1-3 disease and received curative-intent surgery. Multivariable analyses assessed the association between surgical approach and patient and disease factors.
Inclusion criteria identified 73,137 patients: 51,408 underwent open surgery and 21,729 received MIPS. In our multivariable analysis, Black race was associated with reduced odds of MIPS (AOR 0.88; p = 0.02), while older age (AOR 1.17; p = 0.01), later year of diagnosis (AOR 1.57; p < 0.001), and private insurance coverage (AOR 1.30; p = 0.05) were associated with increased odds. When patients with adenocarcinoma were analyzed in isolation, disparities in MIPS utilization persisted even when controlling for disease stage.
Sociodemographic factors like age, race, and insurance coverage appear to vary in the utilization of MIPS technologies for the treatment of pancreatic malignancy. Addressing variation with robust mixed methods approaches in the future is proposed to incorporate prospective interventions with highly annotated outcomes for additional study.
微创胰腺手术(MIPS)在选择性应用时已被证明可以加速恢复,且结果与开放方法相当,但可能无法公平地获得。本研究探讨了 MIPS 在胰腺癌中的应用差异。
国家癌症数据库被用来确定 2010 年至 2020 年间诊断为原发性胰腺肿瘤的患者。研究参与者的临床或病理分期为 1-3 期,并接受了根治性手术。多变量分析评估了手术方式与患者和疾病因素之间的关系。
纳入标准确定了 73137 例患者:51408 例接受了开放手术,21729 例接受了 MIPS。在我们的多变量分析中,黑人种族与 MIPS 的可能性降低相关(AOR 0.88;p=0.02),而年龄较大(AOR 1.17;p=0.01)、较晚的诊断年份(AOR 1.57;p<0.001)和私人保险覆盖(AOR 1.30;p=0.05)与可能性增加相关。当单独分析腺癌患者时,即使控制了疾病分期,MIPS 利用的差异仍然存在。
年龄、种族和保险覆盖等社会人口因素似乎在 MIPS 技术治疗胰腺恶性肿瘤的应用中存在差异。建议未来采用强有力的混合方法方法来解决这些差异,纳入具有高度注释结果的前瞻性干预措施,以进行进一步研究。